Critical Survey: Regenicin (OTCMKTS:RGIN) versus Vivos Therapeutics (NASDAQ:VVOS)

Regenicin (OTCMKTS:RGIN) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk.

Earnings and Valuation

This table compares Regenicin and Vivos Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regenicin	N/A	N/A	-$640,000.00	N/A	N/A
Vivos Therapeutics	$14.58 million	1.40	-$13.58 million	($5.68)	-0.61

Regenicin has higher earnings, but lower revenue than Vivos Therapeutics.

Profitability

This table compares Regenicin and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Regenicin	N/A	N/A	N/A
Vivos Therapeutics	-86.19%	-335.04%	-93.58%

Volatility and Risk

Regenicin has a beta of -18.91, meaning that its stock price is 1,991% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.47, meaning that its stock price is 647% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Regenicin and Vivos Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regenicin	0	0	0	0	0.00
Vivos Therapeutics	0	0	2	0	3.00

Vivos Therapeutics has a consensus target price of $6.30, indicating a potential upside of 81.56%. Given Vivos Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than Regenicin.

Insider & Institutional Ownership

0.0% of Regenicin shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 3.0% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Vivos Therapeutics beats Regenicin on 7 of the 11 factors compared between the two stocks.

About Regenicin

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.